



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Khan et al.

Serial No.: 10/028,075

Filed: December 21, 2001

For: GENE REGULATOR

Confirmation No.: 1102

Examiner: T. McKelvey

Group Art Unit: 1636

Attorney Docket No.: 2183-5223US

NOTICE OF EXPRESS MAILING

Express Mail Mailing Label Number: EL995984633US

Date of Deposit with USPS: June 30, 2006

Person making Deposit: Wendy Neff

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In compliance with the duty to disclose information material to patentability pursuant to 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO/SB/08 be considered by the Examiner and made of record. Copies of the listed documents are enclosed pursuant to 37 C.F.R. § 1.98(a).

U.S. Patent Documents

<u>U.S. Patent No.</u>	<u>Publication Date</u>	<u>Patentee</u>
US - 6,727,227	04-27-2004	Khavinson

Foreign Patent Documents

<u>Document No.</u>	<u>Publication Date</u>	<u>Patentee</u>
WO 01/29067	04-26-2001	Obschestvo S Ogranichennoi Otvetstvennostiju "Klinika Instituta Bioregulyatsii I Gerontologii"

Other Documents

KACHRA et al., "Low Molecular Weight Components but Not Dimeric HCG Inhibit Growth and Down-Regulate AP-1 Transcription Factor in Kaposi's Sarcoma Cells," Endocrinology, 1997, pp. 4038-4041, vol. 138, no. 9.

KHAVINSON et al., "Mechanisms Underlying Geroprotective Effects of Peptides," Bulletin of Experimental Biology and Medicine, January 2002, pp. 1-5, Vol. 133, No. 1.

KHAVINSON et al., "Peptide Promotes Overcoming of the Division Limit in Human Somatic Cell," Bulletin of Experimental Biology and Medicine, May 2004, pp. 503-506, Vol. 137, No. 5.

MOROZOV et al., "Natural and Synthetic Thymic Peptides as Therapeutics for Immune Dysfunction," Int. J. Immunopharmac., 1997, pp. 501-505, Vol. 19, No. 9/10.

KHAVINSON et al., "Inductive Activity of Retinal Peptides," Bulletin of Experimental Biology and Medicine, November 2002, pp. 482-484, Vol. 134, No. 5.

KHAVINSON et al., "Effects of Short Peptides on Lymphocyte Chromatin in Senile Subjects," Bulletin of Experimental Biology and Medicine, January 2004, pp. 78-81, Vol. 137, No. 1.

KHAVINSON et al., "Effects of Livagen Peptide on Chromatin Activation in Lymphocytes from Old People," Bulletin of Experimental Biology and Medicine, October 2002, pp. 389-392, Vol. 134, No. 4.

KHAVINSON et al., "Epithalon Peptide Induces Telomerase Activity and Telomere Elongation in Human Somatic Cells," Bulletin of Experimental Biology and Medicine, June 2003, pp. 590-592, Vol. 135, No. 6.

IVANOV et al., "Hemoglobin as a Source of Endogenous Bioactive Peptides: The Concept of Tissue-Specific Peptide Pool," Biopolymers, 1997, pp. 171-188, Vol. 39.

KHAVINSON et al, Gerontological Aspects of Genome Peptide Regulation, 2005, S. Karger AG, Basel, Switzerland.

In compliance with the duty to disclose information material to patentability pursuant to 37 C.F.R. § 1.56, Applicants hereby identify the following listed copending applications naming a common inventor(s):

Attorney Docket No.: 3077-6084US
Serial No.: 10/753,510
Filed: 1/7/2004
Title: IMMUNOREGULATORY COMPOSITIONS

Attorney Docket No.: 2183-6400US
Serial No.: 10/817,756
Filed: 4/2/2004
Title: GENE REGULATORY PEPTIDES

Attorney Docket No.: 3077-6384US
Serial No.: 10/821,240
Filed: 4/8/2004
Title: METHODS AND USES FOR PROTEIN BREAKDOWN PRODUCTS

Attorney Docket No.: 3077-6420US
Serial No.: 10/821,256
Filed: 4/8/2004
Title: COMPOSITIONS CAPABLE OF REDUCING ELEVATED BLOOD UREA CONCENTRATION

Serial No.: 10/028,075

Attorney Docket No.: 2183-4799.1US
Serial No.: 11/037,972
Filed: 1/18/2005
Title: IMMUNOREGULATOR

Attorney Docket No.: 3077-6418US
Serial No.: 11/243,438
Filed: 10/4/2005
Title: COMPOSITIONS FOR MUCOSAL AND ORAL
ADMINISTRATION COMPRISING HCG FRAGMENTS

Attorney Docket No.: 3077-6420.2US
Serial No.: 11/249,541
Filed: 10/13/2005
Title: COMPOSITIONS CAPABLE OF REDUCING ELEVATED BLOOD
UREA CONCENTRATION

Attorney Docket No.: 3077-7568US
Serial No.: 11/286,571
Filed: 11/23/2005
Title: COMPOUNDS OF THERAPEUTIC VALUE IN THE TREATMENT
OF MULTIPLE SCLEROSIS AND OTHER DISEASES WHEREIN
FOAM CELLS ARE INVOLVED IN THE DISEASE ETIOLOGY

Attorney Docket No.: 3077-7643US
Serial No.: 11/346,450
Filed: 2/2/2006
Title: COMPOSITIONS CAPABLE OF REDUCING ELEVATED BLOOD
UREA CONCENTRATION


Attorney Docket No.: 3077-7568.1US
Serial No.: 11/346,761
Filed: 2/3/2006
Title: COMPOUNDS OF THERAPEUTIC VALUE IN THE TREATMENT
OF MULTIPLE SCLEROSIS AND OTHER DISEASES WHEREIN
FOAM CELLS ARE INVOLVED IN THE DISEASE ETIOLOGY

Attorney Docket No.: 2183-7849US
Serial No.: 11/446,458
Filed: 6/2/2006
Title: METHOD TO DIAGNOSE OR SCREEN FOR INFLAMMATORY
DISEASES

Serial No.: 10/028,075

This Supplemental Information Disclosure Statement is believed to be filed before the mailing date of the first Office Action on the merits subsequent to the filing of an RCE in the above-identified application.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'Yuri M. Colton', is written over the typed name.

Yuri M. Colton, Ph.D.
Registration No. 55,081
Attorney for Applicants
TRASKBRITT, P.C.
P.O. Box 2550
Salt Lake City, Utah 84110-2550
Telephone: 801-532-1922

Date: June 30, 2006
ACT/alb

Enclosures: Form PTO/SB/08
Copy of documents cited

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	1	of	2
-------	---	----	---

Complete if Known

Application Number	10/028,075
Filing Date	December 21, 2001
First Named Inventor	Khan et al.
Group Art Unit	1636
Examiner Name	T. McKelvey
Attorney Docket Number	2183-5223US

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

2

of

2

Complete if Known

Application Number	10/028,075
Filing Date	December 21, 2001
First Named Inventor	Khan et al.
Group Art Unit	1636
Examiner Name	T. McKelvey
Attorney Docket Number	2183-5223US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		KACHRA et al., "Low Molecular Weight Components but Not Dimeric HCG Inhibit Growth and Down-Regulate AP-1 Transcription Factor in Kaposi's Sarcoma Cells," Endocrinology, 1997, pp. 4038-4041, vol. 138, no. 9.	
		KHAVINSON et al., "Mechanisms Underlying Geroprotective Effects of Peptides," Bulletin of Experimental Biology and Medicine, January 2002, pp. 1-5, Vol. 133, No. 1.	
		KHAVINSON et al., "Peptide Promotes Overcoming of the Division Limit in Human Somatic Cell," Bulletin of Experimental Biology and Medicine, May 2004, pp. 503-506, Vol. 137, No. 5.	
		MOROZOV et al., "Natural and Synthetic Thymic Peptides as Therapeutics for Immune Dysfunction," Int. J. Immunopharmac., 1997, pp. 501-505, Vol. 19, No. 9/10.	
		KHAVINSON et al., "Inductive Activity of Retinal Peptides," Bulletin of Experimental Biology and Medicine, November 2002, pp. 482-484, Vol. 134, No. 5.	
		KHAVINSON et al., "Effects of Short Peptides on Lymphocyte Chromatin in Senile Subjects," Bulletin of Experimental Biology and Medicine, January 2004, pp. 78-81, Vol. 137, No. 1.	
		KHAVINSON et al., "Effects of Livagen Peptide on Chromatin Activation in Lymphocytes from Old People," Bulletin of Experimental Biology and Medicine, October 2002, pp. 389-392, Vol. 134, No. 4.	
		KHAVINSON et al., "Epithalon Peptide Induces Telomerase Activity and Telomere Elongation in Human Somatic Cells," Bulletin of Experimental Biology and Medicine, June 2003, pp. 590-592, Vol. 135, No. 6.	
		IVANOV et al., "Hemoglobin as a Source of Endogenous Bioactive Peptides: The Concept of Tissue-Specific Peptide Pool," Biopolymers, 1997, pp. 171-188, Vol. 39.	
		KHAVINSON et al, Gerontological Aspects of Genome Peptide Regulation, 2005, S. Karger AG, Basel, Switzerland.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.